[开放获取]   中国慢性诱导性荨麻疹诊治专家共识（2023）

doi:10.35541/cjd.20220819

Abstract

Abstract: 【Abstract】 Chronic inducible urticaria is a group of chronic urticaria induced by specific triggers, with wheal and/or angioedema as main clinical manifestations, which may be accompanied by itching, tingling, burning sensation, pain and other unpleasant symptoms. This group of diseases are characterized by highly heterogeneous clinical manifestations, long courses, and recurrent symptoms, which have a great impact on the quality of life of patients. Based on progress in Chinese and international clinical studies on the diagnosis and treatment of chronic inducible urticaria in recent years, the Immunology Group of Chinese Society of Dermatology extensively consulted experts through the Delphi method, and finally developed this consensus after several rounds of discussion among relevant experts, in order to improve clinicians' understanding of this group of diseases and standardize their diagnosis and treatment.

Key words: Urticaria, Chronic inducible urticaria, Symptomatic dermographism, Cold contact urticaria, Cholinergic urticaria, Diagnosis, Treatment, Expert consensus

Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）[J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.doi:10.35541/cjd.20220819

References ［67］

［1］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA（2） LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884.
［2］	陈奇权, 杨显杰, 顾恒, 等. 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》. 中华皮肤科杂志, 2023,e20220814. doi: 10.35541/cjd.20220814.
［3］	Zhong H, Song Z, Chen W, et al. Chronic urticaria in Chinese population: a hospital⁃based multicenter epidemiological study［J］. Allergy, 2014,69（3）:359⁃364. doi: 10.1111/all.12338.
［4］	Napolitano M, Fabbrocini G, Stingeni L, et al. Prevalence of chronic inducible urticaria in elderly patients［J］. J Clin Med, 2021,10（2）:247. doi: 10.3390/jcm10020247.
［5］	Li J, Mao D, Liu S, et al. Epidemiology of urticaria in China: a population⁃based study［J］. Chin Med J （Engl）, 2022,135（11）:1369⁃1375. doi: 10.1097/CM9.0000000000002172.
［6］	Kulthanan K, Ungprasert P, Tuchinda P, et al. Symptomatic dermographism: a systematic review of treatment options［J］. J Allergy Clin Immunol Pract, 2020,8（9）:3141⁃3161. doi: 10. 1016/j.jaip.2020.05.016.
［7］	Kulthanan K, Ungprasert P, Tapechum S, et al. Vibratory angioedema subgroups, features, and treatment: results of a systematic review［J］. J Allergy Clin Immunol Pract, 2021,9（2）:971⁃984. doi: 10.1016/j.jaip.2020.09.009.
［8］	Wang F, Zhao YK, Luo ZY, et al. Aquagenic cutaneous disorders［J］. J Dtsch Dermatol Ges, 2017,15（6）:602⁃608. doi: 10.1111/ddg.13234.
［9］	Altrichter S, Koch K, Church MK, et al. Atopic predisposition in cholinergic urticaria patients and its implications［J］. J Eur Acad Dermatol Venereol, 2016,30（12）:2060⁃2065. doi: 10.1111/jdv.13765.
［10］	Raison⁃Peyron N, Philibert C, Bernard N, et al. Cold contact urticaria following vaccination: four cases［J］. Acta Derm Venereol, 2016,96（6）:852⁃853. doi: 10.2340/00015555⁃2358.
［11］	Raison⁃Peyron N, Litovsky J, Huet P, et al. Cold contact urticaria triggered by a permanent tattoo［J］. J Cosmet Dermatol, 2021,20（8）:2463⁃2465. doi: 10.1111/jocd.13874.
［12］	Yücel MB, Ertas R, Türk M, et al. Food⁃dependent and food⁃exacerbated symptomatic dermographism: new variants of symptomatic dermographism［J］. J Allergy Clin Immunol, 2022,149（2）:788⁃790. doi: 10.1016/j.jaci.2021.07.030.
［13］	Liu R, Peng C, Jing D, et al. Identification of gut microbiota signatures in symptomatic dermographism［J］. Exp Dermatol, 2021,30（12）:1794⁃1799. doi: 10.1111/exd.14326.
［14］	Maltseva N, Borzova E, Fomina D, et al. Cold urticaria ⁃ What we know and what we do not know［J］. Allergy, 2021,76（4）:1077⁃1094. doi: 10.1111/all.14674.
［15］	Lawlor F, Black AK. Delayed pressure urticaria［J］. Immunol Allergy Clin North Am, 2004,24（2）:247⁃258, vi⁃vii. doi: 10. 1016/j.iac.2004.01.006.
［16］	Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management［J］. Clin Auton Res, 2018,28（1）:103⁃113. doi: 10.1007/s10286⁃017⁃0418⁃6.
［17］	Lugović Mihić L, Bulat V, Situm M, et al. Allergic hypersensitivity skin reactions following sun exposure［J］. Coll Antropol, 2008,32 Suppl 2:153⁃157.
［18］	Giménez⁃Arnau AM, Ribas⁃Llauradó C, Mohammad⁃Porras N, et al. IgE and high⁃affinity IgE receptor in chronic inducible urticaria, pathogenic, and management relevance［J］. Clin Transl Allergy, 2022,12（2）:e12117. doi: 10.1002/clt2.12117.
［19］	Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence［J］. J Allergy Clin Immunol, 2018,141（2）:638⁃649. doi: 10.1016/j.jaci.2017.06.032.
［20］	Lenormand C, Lipsker D. Efficiency of interleukin⁃1 blockade in refractory delayed⁃pressure urticaria［J］. Ann Intern Med, 2012,157（8）:599⁃600. doi: 10.7326/0003⁃4819⁃157⁃8⁃201210160⁃00023.
［21］	Pezzolo E, Peroni A, Gisondi P, et al. Heat urticaria: a revision of published cases with an update on classification and management［J］. Br J Dermatol, 2016,175（3）:473⁃478. doi: 10.1111/bjd.14543.
［22］	刘鑫, 刘念, 陈宏翔. 接触性荨麻疹诊治进展［J］. 中华皮肤科杂志, 2021,54（12）:1114⁃1117. doi: 10.35541/cjd.20200079.
［23］	Schoepke N, Młynek A, Weller K, et al. Symptomatic dermographism: an inadequately described disease［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:708⁃712. doi: 10.1111/jdv.12661.
［24］	Mellerowicz EJ, Asady A, Maurer M, et al. Angioedema frequently occurs in cholinergic urticaria［J］. J Allergy Clin Immunol Pract, 2019,7（4）:1355⁃1357.e1. doi: 10.1016/j.jaip. 2018.10.013.
［25］	Sánchez J, Amaya E, Acevedo A, et al. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors［J］. J Allergy Clin Immunol Pract, 2017,5（2）:464⁃470. doi: 10.1016/j.jaip.2016.09.029.
［26］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all. 15090.
［27］	Schoepke N, Abajian M, Church MK, et al. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism［J］. Clin Exp Dermatol, 2015,40（4）:399⁃403. doi: 10.1111/ced.12547.
［28］	Magerl M, Abajian M, Krause K, et al. An improved Peltier effect⁃based instrument for critical temperature threshold measurement in cold⁃ and heat⁃induced urticaria［J］. J Eur Acad Dermatol Venereol, 2015,29（10）:2043⁃2045. doi: 10.1111/jdv.12739.
［29］	Gaebelein⁃Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: clinic, diagnostic, course and therapy management in 27 patients［J］. J Dtsch Dermatol Ges, 2020,18（11）:1261⁃1268. doi: 10.1111/ddg.14309.
［30］	Vergara⁃de⁃la⁃Campa L, Gatica⁃Ortega ME, Pastor⁃Nieto MA, et al. Vibratory urticaria⁃angioedema: further insights into the response patterns to vortex provocation test［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:e699⁃e701. doi: 10.1111/jdv. 16396.
［31］	Fukunaga A, Oda Y, Imamura S, et al. Cholinergic urticaria: subtype classification and clinical approach［J］. Am J Clin Dermatol, 2022:1⁃14. doi: 10.1007/s40257⁃022⁃00728⁃6.
［32］	Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372, 1372.e1⁃6. doi: 10. 1016/j.jaci.2013.12.1076.
［33］	Metz M, Ohanyan T, Church MK, et al. Omalizumab is an effective and rapidly acting therapy in difficult⁃to⁃treat chronic urticaria: a retrospective clinical analysis［J］. J Dermatol Sci, 2014,73（1）:57⁃62. doi: 10.1016/j.jdermsci.2013.08.011.
［34］	Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire （CU⁃QoL）［J］. Allergy, 2005,60（8）:1073⁃1078. doi: 10.1111/j.1398⁃9995.2005.00833.x.
［35］	Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
［36］	Koch K, Weller K, Werner A, et al. Antihistamine updosing reduces disease activity in patients with difficult⁃to⁃treat cholinergic urticaria［J］. J Allergy Clin Immunol, 2016,138（5）:1483⁃1485.e9. doi: 10.1016/j.jaci.2016.05.026.
［37］	Ruft J, Asady A, Staubach P, et al. Development and validation of the Cholinergic Urticaria Quality⁃of⁃Life Questionnaire （CholU⁃QoL）［J］. Clin Exp Allergy, 2018,48（4）:433⁃444. doi: 10.1111/cea.13102.
［38］	Młynek A, Magerl M, Siebenhaar F, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria［J］. Br J Dermatol, 2010,162（1）:198⁃200. doi: 10.1111/j.1365⁃2133.2009.09441.x.
［39］	Ahsan DM, Altrichter S, Gutsche A, et al. Development of the cold urticaria activity score［J］. Allergy, 2022,77（8）:2509⁃2519. doi: 10.1111/all.15310.
［40］	Aguilera P. Inducing light tolerance with narrowband UV⁃B therapy in solar urticaria［J］. Actas Dermosifiliogr （Engl Ed）, 2018,109（10）:853. doi: 10.1016/j.ad.2018.06.009.
［41］	Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse⁃controlled ergometry test for diagnosing and investigating cholinergic urticaria［J］. J Dermatol Sci, 2014,75（2）:88⁃93. doi: 10.1016/j.jdermsci.2014.04.007.
［42］	Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: a systematic review of treatment options［J］. J Allergy Clin Immunol, 2018,141（5）:1726⁃1734. doi: 10.1016/j.jaci.2018. 01.031.
［43］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［44］	Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1119⁃1130. doi: 10.1016/j.jaip.2018.03.007.
［45］	He ZH, Qiu SC, Huang ZW, et al. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: a systematic review and meta⁃analysis［J］. Dermatol Ther, 2022,35（12）:e15928. doi: 10.1111/dth.15928.
［46］	Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations［J］. BMJ, 2004,328（7454）:1490. doi: 10.1136/bmj.328.7454.1490.
［47］	Fialek M, Dezoteux F, Le Moing A, et al. Omalizumab in chronic inducible urticaria: a retrospective, real⁃life study［J］. Ann Dermatol Venereol, 2021,148（4）:262⁃265. doi: 10.1016/j.annder. 2021.04.010.
［48］	Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism⁃results of a randomized placebo⁃controlled trial［J］. J Allergy Clin Immunol, 2017,140（3）:870⁃873.e5. doi: 10.1016/j.jaci.2017.01.042.
［49］	Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria⁃results of a randomized placebo⁃controlled trial［J］. J Allergy Clin Immunol, 2017,140（3）:864⁃867.e5. doi: 10.1016/j.jaci.2017.01.043.
［50］	Gastaminza G, Azofra J, Nunez⁃Cordoba JM, et al. Efficacy and safety of omalizumab （Xolair） for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double⁃blind and open⁃label placebo⁃controlled clinical trial［J］. J Allergy Clin Immunol Pract, 2019,7（5）:1599⁃1609.e1. doi: 10.1016/j.jaip.2018.12.025.
［51］	Aubin F, Avenel⁃Audran M, Jeanmougin M, et al. Omalizumab in patients with severe and refractory solar urticaria: a phase II multicentric study［J］. J Am Acad Dermatol, 2016,74（3）:574⁃575. doi: 10.1016/j.jaad.2015.11.021.
［52］	Bonnekoh H, Terhorst⁃Molawi D, Buttgereit T, et al. Treatment of severe heat urticaria with omalizumab ⁃ report of a case and review of the literature［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:e489⁃e491. doi: 10.1111/jdv.16407.
［53］	Rorie A, Gierer S. A case of aquagenic urticaria successfully treated with omalizumab［J］. J Allergy Clin Immunol Pract, 2016,4（3）:547⁃548. doi: 10.1016/j.jaip.2015.12.017.
［54］	Pressler A, Grosber M, Halle M, et al. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio⁃oedema［J］. Clin Exp Dermatol, 2013,38（2）:151⁃153. doi: 10.1111/j.1365⁃2230.2012.04430.x.
［55］	Can PK, Salman A, Hoşgören⁃Tekin S, et al. Effectiveness of omalizumab in patients with chronic inducible urticaria: real⁃life experience from two UCARE centres［J］. J Eur Acad Dermatol Venereol, 2021,35（10）:e679⁃e682. doi: 10.1111/jdv.17385.
［56］	Gorczyza M, Schoepke N, Krause K, et al. Patients with chronic cold urticaria may benefit from doxycycline therapy［J］. Br J Dermatol, 2017,176（1）:259⁃261. doi: 10.1111/bjd.14820.
［57］	Hannuksela M, Kokkonen EL. Ultraviolet light therapy in chronic urticaria［J］. Acta Derm Venereol, 1985,65（5）:449⁃450.
［58］	Levi A, Enk CD. Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity［J］. Photodermatol Photoimmunol Photomed, 2015,31（6）:302⁃306. doi: 10.1111/phpp.12186.
［59］	Borzova E, Rutherford A, Konstantinou GN, et al. Narrowband ultraviolet B phototherapy is beneficial in antihistamine⁃resistant symptomatic dermographism: a pilot study［J］. J Am Acad Dermatol, 2008,59（5）:752⁃757. doi: 10.1016/j.jaad.2008. 07.016.
［60］	Maksimovic L, Frémont G, Jeanmougin M, et al. Solar urticaria successfully treated with intravenous immunoglobulins［J］. Dermatology, 2009,218（3）:252⁃254. doi: 10.1159/000193998.
［61］	Kulthanan K, Ungprasert P, Tuchinda P, et al. Delayed pressure urticaria: a systematic review of treatment options［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2035⁃2049.e5. doi: 10.1016/j.jaip.2020.03.004.
［62］	Kozaru T, Fukunaga A, Taguchi K, et al. Rapid desensitization with autologous sweat in cholinergic urticaria［J］. Allergol Int, 2011,60（3）:277⁃281. doi: 10.2332/allergolint.10⁃OA⁃0269.
［63］	Rujitharanawong C, Kulthanan K, Tuchinda P, et al. A systematic review of aquagenic urticaria⁃subgroups and treatment options［J］. J Allergy Clin Immunol Pract, 2022,10（8）:2154⁃2162. doi: 10.1016/j.jaip.2022.04.033.
［64］	Kozel MM, Mekkes JR, Bossuyt PM, et al. Natural course of physical and chronic urticaria and angioedema in 220 patients［J］. J Am Acad Dermatol, 2001,45（3）:387⁃391. doi: 10.1067/mjd.2001.116217.
［65］	Bal F, Kahveci M, Soyer O, et al. Chronic inducible urticaria subtypes in children: clinical features and prognosis［J］. Pediatr Allergy Immunol, 2021,32（1）:146⁃152. doi: 10.1111/pai.13324.
［66］	Dover JS, Black AK, Ward AM, et al. Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients［J］. J Am Acad Dermatol, 1988,18（6）:1289⁃1298. doi: 10.1016/s0190⁃9622（88）70137⁃1.
［67］	Kim JE, Eun YS, Park YM, et al. Clinical characteristics of cholinergic urticaria in Korea［J］. Ann Dermatol, 2014,26（2）:189⁃194. doi: 10.5021/ad.2014.26.2.189.

[1]	Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.
[2]	Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update [J]. Chinese Journal of Dermatology, 2023, 56(6): 559-562.
[3]	Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544.
[4]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[5]	Zhang Liming, Xiao Ting. Update of the autoimmune pathogenesis of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 567-570.
[6]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[7]	Chen Qiquan, Kong Minmin, Yang Xianjie, Wang Huan, Li Jian, Zhang Mingwang, Song Zhiqiang. Clinical analysis of allergen reactivity and atopic disease history in 168 patients with chronic inducible urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 496-503.
[8]	Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517.
[9]	Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530.
[10]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[11]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[12]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on treat-to-target in chronic spontaneous urticaria （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 489-495.
[13]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[14]	Hu Qingjie, Zhou Min, Yao Xu. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis [J]. Chinese Journal of Dermatology, 2023, 56(5): 410-414.
[15]	Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388.

Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［67］

Related Articles 15

Metrics

Comments

Recommended 10